Report of the IWGT working group on strategy/interpretation for regulatory in vivo tests. II. Identification of in vivo-only positive compounds in the bone marrow micronucleus test

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 627, Issue 1, 2007, Pages 92-105

  Tweats, D J ^a   Blakey, D ^b   Heflich, R H ^c   Jacobs, A ^d   Jacobsen, S D ^e   Morita, T ^f   Nohmi, T ^f   O'Donovan, M R ^g   Sasaki, Y F ^h   Sofuni, T ^f   Tice, R ⁱ  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b HEALTH CANADA   (Canada)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e NOVO NORDISK A S   (Denmark)

^f NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^g ASTRAZENECA   (United Kingdom)

^h HACHINOHE NATIONAL COLLEGE OF TECHNOLOGY   (Japan)

ⁱ NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

ADME; Cosmetics; Food additives; Genotoxicity tests; In vitro versus in vivo metabolism; In vitro only genotoxicity test batteries; In vivo; In vivo only positive compounds; Influence of gut flora; IWGT; Kinase inhibitors; Micronucleus test; Pharmaceuticals; Pharmacological mechanisms; Regulatory implication; Rodent bone marrow; Sex specific metabolism

Indexed keywords

BENZENE; CISPLATIN; COSMETIC; FOLIC ACID; FOOD ADDITIVE; INDUSTRIAL CHEMICAL; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MORPHINE; MUTAGENIC AGENT; PEMETREXED; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; URETHAN;

ARTICLE; BONE MARROW; CELL CYCLE; CHROMOSOME BREAKAGE; ENZYME INHIBITION; GENOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLORA; LUNG NON SMALL CELL CANCER; METABOLISM; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; QUESTIONNAIRE;

ANIMALS; BENZENE; BONE MARROW; ENZYME INHIBITORS; GLUTAMATES; GUANINE; MAP KINASE KINASE KINASES; MICRONUCLEUS TESTS; MORPHINE; RODENTIA; SENSITIVITY AND SPECIFICITY; SULFAPYRIDINE; SULFASALAZINE; URETHANE;

RODENTIA;

EID: 33846193238     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2006.10.006     Document Type: Article

References (40)

1. Müller L., Blakey D., Dearfield K.L., Galloway S., Guzzie P., Hayashi M., Kasper P., Kirkland D., MacGregor J.T., Parry J.M., Schechtman L., Smith A., Tanaka N., Tweats D., and Yamasaki H. Strategy for genotoxicity testing and stratification of genotoxicity test results-report of the initial activities of the IWGT Expert Group. Mutat. Res. 540 (2003) 177-181
2. Inai K., Arihiro K., Takeshima Y., Yonehara S., Tachiyama Y., Khatum N., and Nishisaka T. Quantitative risk assessment of carcinogenicity of urethane (ethyl carbamate) on the basis of long-term oral administration to B6C3F1 mice. Jpn. J. Cancer Res. 82 (1991) 380-385
3. IARC, Urethane, IARC Monograph. Some Anti-thyroid and Related Substances, Nitrofurans and Industrial Chemicals, vol. 7, 1974, pp. 111-140.
4. Anderson D., and Styles J.A. An evaluation of 6 short-term tests for detecting organic chemical carcinogens. Appendix 2. The bacterial mutation test. Br. J. Cancer 37 (1974) 924-930
5. Ishidate Jr. M., Harnois M.C., and Sofuni T. A comparative analysis of data on the clastogenicity of 951 chemical substances tested in mammalian cell cultures. Mutat. Res. 195 (1988) 151-213
6. Hubner P., Groux P.M., Weibel B., Sengstag C., Horlbeck J., Leong-Morgenthaler P.-M., and Luthy J. Genotoxicity of ethyl carbamate (urethane) in Salmonella, yeast and human lymphoblastoid cells. Mutat. Res. 390 (1997) 11-19
7. Sotomayor R.E., and Collins T.F.X. Mutagenicity, metabolism and DNA interactions of urethane. Toxicol. Ind. Health 6 (1990) 71-108
8. Ashby J., Tinwell H., and Callander R.D. Activity of urethane and N,N′-dimethylurethane in the mouse bone marrow micronucleus assay; equivalence of oral and intraperitoneal routes of exposure. Mutat. Res. 245 (1990) 227-230
9. Williams C.V., Fletcher K., Tinwell H., and Ashby J. Weak mutagenicity of ethyl carbamate to Lac-Z transgenic mice. Mutagenesis 13 (1998) 133-137
10. Mirsalis J.C., Shimon J.A., Johnson A., Fairchild D., Kanazawa N., Nguyen T., de Boer J., Glickman B., and Winegar R.A. Evaluation of mutant frequencies of chemically induced tumors and normal tissues in lambda/cII transgenic mice. Environ. Mol. Mutagen. 45 (2005) 17-35
11. 32P-postlabelling in liver and lung DNA of mice treated with ethyl carbamate (urethane) or it's metabolites. Carcinogenesis 17 (1996) 1711-1718
12. Forkert P.G., and Lee R.P. Metabolism of ethyl carbamate by pulmonary cytochrome P450 and carboxylesterase isozymes: involvement of CYP2E1 and hydrolase A. Toxicol. Appl. Pharmacol. 146 (1997) 245-254
13. Guegerich F.P., and Kim D.-H. Enzymatic oxidation of ethyl carbamate to vinyl carbamate and its role as an intermediate in the formation of 1,N6-ethenoadenosine. Chem. Res. Toxicol. 4 (1991) 413-421
14. Hoffler U., Dixon D., Peddada S., and Ghanayem B.I. Inhibition of urethane-induced genotoxicity and cell proliferation in CYP2E1-null mice. Mutat. Res. 572 (2005) 58-72
15. Burke D.A., Wedd D.J., Herriott D., Bayliss M.K., Spalding D.J., and Wilcox P. Evaluation of pyrazole and ethanol induced S9 fraction in bacterial mutagenicity testing. Mutagenesis 9 (1994) 23-29
16. Whysner J., Reddy M.V., Ross P.M., Mohan M., and Lax E.A. Genotoxicity of benzene and its metabolites. Mutat. Res. 566 (2004) 99-130
17. Bishop J.B., Witt K.L., Gulati D.K., and MacGregor J.T. Evaluation of the mutagenicity of the anti-inflammatory drug salicylazosulfapyridine. Mutagenesis 5 (1990) 549-554
18. Witt K.L., Bishop J.B., McFee A.F., and Kumaroo V. Induction of chromosomal damage in mammalian cells in vitro and in vivo by sulfapyridine or 5-aminosalicylic acid. Mutat. Res. 283 (1992) 59-64
19. Witt K.L., Gudi R., and Bishop J.B. Induction of kinetochore positive and negative micronuclei in mouse bone marrow cells by salicylazosulfapyridine and sulfapyridine. Mutat. Res. 283 (1992) 53-57
20. Eskine I.A., Mackay J.M., and Fox D.P. Monitoring patients on long-term drug therapy for genotoxic effects. Basic Life Sci. 29 (1984) 895-905
21. Fox D.P., Mackay J.M., Brunt P.W., Hawksworth G.M., and Brown J. Abnormal chromosomes and sulfasalazine therapy. 5-ASA: The State of the Art, The Medicine Publishing Foundation Symposium, Series 21 (1987), MES Medical Education Services, Toronto 15-28
22. Pironi L., Cornia G.L., Ursitti M.A., Dallasta M.A., Miniero R., Fasano F., Miglioli M., and Barbara L. Evaluation of oral administration of folic and folinic acid to prevent folate deficiency in patients with inflammatory bowel disease treated with salicylazosulfapyridine. Int. J. Clin. Pharmacol. Res. 8 (1988) 143-148
23. Krogh Jensen M., Ekelund S., and Svendsen L. Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. Scand. J. Clin. Lab. Invest. 56 (1996) 421-429
24. NTP. NTP toxicology and carcinogenesis studies of salicylazosulfapyridine (CAS no. 599-79-1) in F344/N rats and B6C3F1 mice (Gavage Studies). Natl. Toxicol. Program Tech. Rep. Ser. 457 (1997) 1-327
25. Everson R.B., Wehr C.M., Erexson G.L., and MacGregor J.T. Association of marginal folate depletion with increased human chromosomal damage in vivo: demonstration by analysis of micronucleated erythrocytes. J. Natl. Cancer Inst. 80 (1988) 525-529
26. MacGregor J.T., Wehr C.M., Hiatt R.A., Peters B., Tucker J.D., Langlois R., Jacob R., Jensen R., Yager J.W., Shigenaga M.K., Frei B., Eynon B., and Ames B.N. "Spontaneous" genetic damage in man: evaluation of interindividual variability, relationship among markers of damage, and influence of nutritional status. Mutat. Res. 377 (1997) 125-135
27. Iatropoulos M.J., Williams G.M., Abdo K.M., Kari F.W., and Hart R.W. Mechanistic studies on genotoxicity and carcinogenicity of salicylazosulfapyridine an anti-inflammatory medicine. Exp. Toxicol. Pathol. 49 (1997) 15-28
28. Heflich R.H., Djuric Z., Zhou Z., Fullerton N.F., Casciano D.A., and Beland F.A. Metabolism of 2-acetylaminofluorene in the Chinese hamster ovary cell mutation assay. Environ. Mol. Mutagen. 11 (1988) 167-181
29. Mackay J.M., Fox D.P., Brunt P.W., Hawksworth G.M., and Brown J.E. In vitro induction of chromosome damage by sulphasalazine in human lymphocytes. Mutat. Res. 222 (1989) 27-36
30. PDR 2005 Physicians Desk Reference (2005), Medical Economics Montvale, NJ
31. Nair M.P., Schwartz S.A., Polasani R., Hou J., Sweet A., and Chadha K.C. Immunoregulatory effects of morphine on human lymphocytes. Clin. Diagn. Lab. Immunol. 4 (1997) 127-132
32. Singhal P., Kapasi A., Reddy K., and Franki N. Opiates promote T cell apoptosis through JNK and caspase pathway. Adv. Exp. Med. Biol. 493 (2001) 127-135
33. Couch D.B., and Sawant S.G. The clastogenicity of morphine sulfate in vivo. Adv. Exp. Med. Biol. 373 (1995) 123-129
34. Sawant S.G., Kozlowski R.S., and Couch D.B. The role of adrenal corticosteroids in induction of micronuclei by morphine. Mutat. Res. 498 (2001) 129-133
35. Baker A.K., and Meert T.F. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice. Pharmacol. Exp. Therap. 302 (2002) 1253-1264
36. Schafer D.A., Xie Y., and Falek A. Detection of opiate-enhanced increases in DNA damage, HPRT mutants and the mutation frequency in human HUT-78 cells. Environ. Mol. Mutagen. 23 (1994) 37-44
37. Willard F.S., and Crouch M.F. MEK, ERK, and p90RSK are present on mitotic tubulin in Swiss 3T3 cells: a role for the MAP kinase pathway in regulating mitotic exit. Cell. Signal. 13 (2001) 653-664
38. Zhang W.L., Huitorel P., Glass R., Fernandez-Serra M., Arnone M.I., Chiri S., Picard A., and Ciapa B. A MAPK pathway is involved in the control of mitosis after fertilization of the sea urchin egg. Dev. Biol. 282 (2005) 192-206
39. Walker D.K., Ackland .M.J., James G.C., Muirhead G.J., Rance D.J., Wastall P., and Wright P.A. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29 (1999) 297-310
40. Kirkland D., Aardema M., Henderson L., and Müller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584 (2005) 1-256